Meta-Analysis

他汀类药物与肝癌发病率的关系:一项最新的荟萃分析

卷 31, 期 6, 2024

发表于: 17 July, 2023

页: [762 - 775] 页: 14

弟呕挨: 10.2174/0929867330666230701000400

open access plus

conference banner
摘要

背景:先前的研究已经发现他汀类药物在预防肝癌方面的潜在作用。 目的:本研究旨在探讨不同类型他汀类药物对肝癌发病率的影响。 方法:系统检索PubMed、EBSCO、Web of Science和Cochrane Library数据库自成立至2022年7月的相关文章,探讨亲脂或亲水他汀类药物暴露与肝癌发病率之间的关系。主要结果是肝癌的发病率。 结果:本荟萃分析纳入了11篇文章。综合结果显示,与未暴露的队列相比,暴露于亲脂性他汀类药物(OR=0.54, p < 0.001)和亲水他汀类药物(OR=0.56, p < 0.001)的患者肝癌发病率降低。亚组分析显示,两种暴露于亲脂性(东方国家:OR=0.51, p < 0.001;西方国家:OR=0.59, p < 0.001)和亲水性(东方国家:OR=0.51, p < 0.001;西方国家:OR=0.66, p=0.019)他汀类药物降低了东西方国家的肝癌发病率,东方国家的降低最为显著。与氟伐他汀、西伐他汀和普伐他汀不同,阿托伐他汀(OR=0.55, p < 0.001)、辛伐他汀(OR=0.59, p < 0.001)、洛伐他汀(OR=0.51, p < 0.001)、匹伐他汀(OR=0.36, p=0.008)和瑞舒伐他汀(OR=0.60, p=0.027)能有效降低肝癌的发生率。 结论:亲脂性和亲水性他汀类药物都有助于预防肝癌。此外,其疗效受使用的区域和特定类型的他汀类药物的影响。

关键词: 肝癌,他汀类,亲脂性他汀类,亲水性他汀类,发病率,荟萃分析。

[1]
Llovet, J.M.; Kelley, R.K.; Villanueva, A.; Singal, A.G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R.S. Hepatocellular carcinoma. Nat. Rev. Dis. Primers, 2021, 7(1), 6.
[http://dx.doi.org/10.1038/s41572-020-00240-3] [PMID: 33479224]
[2]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[3]
Benson, A.B.; D’Angelica, M.I.; Abbott, D.E.; Anaya, D.A.; Anders, R.; Are, C.; Bachini, M.; Borad, M.; Brown, D.; Burgoyne, A.; Chahal, P.; Chang, D.T.; Cloyd, J.; Covey, A.M.; Glazer, E.S.; Goyal, L.; Hawkins, W.G.; Iyer, R.; Jacob, R.; Kelley, R.K.; Kim, R.; Levine, M.; Palta, M.; Park, J.O.; Raman, S.; Reddy, S.; Sahai, V.; Schefter, T.; Singh, G.; Stein, S.; Vauthey, J.N.; Venook, A.P.; Yopp, A.; McMillian, N.R.; Hochstetler, C.; Darlow, S.D. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2021, 19(5), 541-565.
[http://dx.doi.org/10.6004/jnccn.2021.0022] [PMID: 34030131]
[4]
Allemani, C.; Matsuda, T.; Di Carlo, V.; Harewood, R.; Matz, M.; Nikšić, M.; Bonaventure, A.; Valkov, M.; Johnson, C.J.; Estève, J.; Ogunbiyi, O.J.; Azevedo e Silva, G.; Chen, W.Q.; Eser, S.; Engholm, G.; Stiller, C.A.; Monnereau, A.; Woods, R.R.; Visser, O.; Lim, G.H.; Aitken, J.; Weir, H.K.; Coleman, M.P.; Bouzbid, S.; Hamdi-Chérif, M.; Zaidi, Z.; Meguenni, K.; Regagba, D.; Bayo, S.; Cheick Bougadari, T.; Manraj, S.S.; Bendahhou, K.; Fabowale, A.; Bradshaw, D.; Somdyala, N.I.M.; Kumcher, I.; Moreno, F.; Calabrano, G.H.; Espinola, S.B.; Carballo Quintero, B.; Fita, R.; Diumenjo, M.C.; Laspada, W.D.; Ibañez, S.G.; Lima, C.A.; De Souza, P.C.F.; Del Pino, K.; Laporte, C.; Curado, M.P.; de Oliveira, J.C.; Veneziano, C.L.A.; Veneziano, D.B.; Latorre, M.R.D.O.; Tanaka, L.F.; Rebelo, M.S.; Santos, M.O.; Galaz, J.C.; Aparicio Aravena, M.; Sanhueza Monsalve, J.; Herrmann, D.A.; Vargas, S.; Herrera, V.M.; Uribe, C.J.; Bravo, L.E.; Garcia, L.S.; Arias-Ortiz, N.E.; Morantes, D.; Jurado, D.M.; Yépez Chamorro, M.C.; Delgado, S.; Ramirez, M.; Galán Alvarez, Y.H.; Torres, P.; Martínez-Reyes, F.; Jaramillo, L.; Quinto, R.; Castillo, J.; Mendoza, M.; Cueva, P.; Yépez, J.G.; Bhakkan, B.; Deloumeaux, J.; Joachim, C.; Macni, J.; Carrillo, R.; Shalkow Klincovstein, J.; Rivera Gomez, R.; Poquioma, E.; Tortolero-Luna, G.; Zavala, D.; Alonso, R.; Barrios, E.; Eckstrand, A.; Nikiforuk, C.; Noonan, G.; Turner, D.; Kumar, E.; Zhang, B.; McCrate, F.R.; Ryan, S.; MacIntyre, M.; Saint-Jacques, N.; Nishri, D.E.; McClure, C.A.; Vriends, K.A.; Kozie, S.; Stuart-Panko, H.; Freeman, T.; George, J.T.; Brockhouse, J.T.; O’Brien, D.K.; Holt, A.; Almon, L.; Kwong, S.; Morris, C.; Rycroft, R.; Mueller, L.; Phillips, C.E.; Brown, H.; Cromartie, B.; Schwartz, A.G.; Vigneau, F.; Levin, G.M.; Wohler, B.; Bayakly, R.; Ward, K.C.; Gomez, S.L.; McKinley, M.; Cress, R.; Green, M.D.; Miyagi, K.; Ruppert, L.P.; Lynch, C.F.; Huang, B.; Tucker, T.C.; Deapen, D.; Liu, L.; Hsieh, M.C.; Wu, X.C.; Schwenn, M.; Gershman, S.T.; Knowlton, R.C.; Alverson, G.; Copeland, G.E.; Bushhouse, S.; Rogers, D.B.; Jackson-Thompson, J.; Lemons, D.; Zimmerman, H.J.; Hood, M.; Roberts-Johnson, J.; Rees, J.R.; Riddle, B.; Pawlish, K.S.; Stroup, A.; Key, C.; Wiggins, C.; Kahn, A.R.; Schymura, M.J.; Radhakrishnan, S.; Rao, C.; Giljahn, L.K.; Slocumb, R.M.; Espinoza, R.E.; Khan, F.; Aird, K.G.; Beran, T.; Rubertone, J.J.; Slack, S.J.; Garcia, L.; Rousseau, D.L.; Janes, T.A.; Schwartz, S.M.; Bolick, S.W.; Hurley, D.M.; Whiteside, M.A.; Miller-Gianturco, P.; Williams, M.A.; Herget, K.; Sweeney, C.; Johnson, A.T.; Keitheri Cheteri, M.B.; Migliore Santiago, P.; Blankenship, S.E.; Farley, S.; Borchers, R.; Malicki, R.; Espinoza, J.R.; Grandpre, J.; Wilson, R.; Edwards, B.K.; Mariotto, A.; Lei, Y.; Wang, N.; Chen, J.S.; Zhou, Y.; He, Y.T.; Song, G.H.; Gu, X.P.; Mei, D.; Mu, H.J.; Ge, H.M.; Wu, T.H.; Li, Y.Y.; Zhao, D.L.; Jin, F.; Zhang, J.H.; Zhu, F.D.; Junhua, Q.; Yang, Y.L.; Jiang, C.X.; Biao, W.; Wang, J.; Li, Q.L.; Yi, H.; Zhou, X.; Dong, J.; Li, W.; Fu, F.X.; Liu, S.Z.; Chen, J.G.; Zhu, J.; Li, Y.H.; Lu, Y.Q.; Fan, M.; Huang, S.Q.; Guo, G.P.; Zhaolai, H.; Wei, K.; Zeng, H.; Demetriou, A.V.; Mang, W.K.; Ngan, K.C.; Kataki, A.C.; Krishnatreya, M.; Jayalekshmi, P.A.; Sebastian, P.; Nandakumar, A.; Malekzadeh, R.; Roshandel, G.; Keinan-Boker, L.; Silverman, B.G.; Ito, H.; Nakagawa, H.; Sato, M.; Tobori, F.; Nakata, I.; Teramoto, N.; Hattori, M.; Kaizaki, Y.; Moki, F.; Sugiyama, H.; Utada, M.; Nishimura, M.; Yoshida, K.; Kurosawa, K.; Nemoto, Y.; Narimatsu, H.; Sakaguchi, M.; Kanemura, S.; Naito, M.; Narisawa, R.; Miyashiro, I.; Nakata, K.; Sato, S.; Yoshii, M.; Oki, I.; Fukushima, N.; Shibata, A.; Iwasa, K.; Ono, C.; Nimri, O.; Jung, K.W.; Won, Y.J.; Alawadhi, E.; Elbasmi, A.; Ab Manan, A.; Adam, F.; Sanjaajmats, E.; Tudev, U.; Ochir, C.; Al Khater, A.M.; El Mistiri, M.M.; Teo, Y.Y.; Chiang, C.J.; Lee, W.C.; Buasom, R.; Sangrajrang, S.; Kamsa-ard, S.; Wiangnon, S.; Daoprasert, K.; Pongnikorn, D.; Leklob, A.; Sangkitipaiboon, S.; Geater, S.L.; Sriplung, H.; Ceylan, O.; Kög, I.; Dirican, O.; Köse, T.; Gurbuz, T.; Karaşahin, F.E.; Turhan, D.; Aktaş, U.; Halat, Y.; Yakut, C.I.; Altinisik, M.; Cavusoglu, Y.; Türkköylü, A.; Üçüncü, N.; Hackl, M.; Zborovskaya, A.A.; Aleinikova, O.V.; Henau, K.; Van Eycken, L.; Valerianova, Z.; Yordanova, M.R.; Šekerija, M.; Dušek, L.; Zvolský, M.; Storm, H.; Innos, K.; Mägi, M.; Malila, N.; Seppä, K.; Jégu, J.; Velten, M.; Cornet, E.; Troussard, X.; Bouvier, A.M.; Guizard, A.V.; Bouvier, V.; Launoy, G.; Arveux, P.; Maynadié, M.; Mounier, M.; Woronoff, A.S.; Daoulas, M.; Robaszkiewicz, M.; Clavel, J.; Goujon, S.; Lacour, B.; Baldi, I.; Pouchieu, C.; Amadeo, B.; Coureau, G.; Orazio, S.; Preux, P.M.; Rharbaoui, F.; Marrer, E.; Trétarre, B.; Colonna, M.; Delafosse, P.; Ligier, K.; Plouvier, S.; Cowppli-Bony, A.; Molinié, F.; Bara, S.; Ganry, O.; Lapôtre-Ledoux, B.; Grosclaude, P.; Bossard, N.; Uhry, Z.; Bray, F.; Piñeros, M.; Stabenow, R.; Wilsdorf-Köhler, H.; Eberle, A.; Luttmann, S.; Löhden, I.; Nennecke, A.L.; Kieschke, J.; Sirri, E.; Emrich, K.; Zeissig, S.R.; Holleczek, B.; Eisemann, N.; Katalinic, A.; Asquez, R.A.; Kumar, V.; Petridou, E.; Ólafsdóttir, E.J.; Tryggvadóttir, L.; Clough-Gorr, K.; Walsh, P.M.; Sundseth, H.; Mazzoleni, G.; Vittadello, F.; Coviello, E.; Cuccaro, F.; Galasso, R.; Sampietro, G.; Giacomin, A.; Magoni, M.; Ardizzone, A.; D’Argenzio, A.; Castaing, M.; Grosso, G.; Lavecchia, A.M.; Sutera Sardo, A.; Gola, G.; Gatti, L.; Ricci, P.; Ferretti, S.; Serraino, D.; Zucchetto, A.; Celesia, M.V.; Filiberti, R.A.; Pannozzo, F.; Melcarne, A.; Quarta, F.; Russo, A.G.; Carrozzi, G.; Cirilli, C.; Cavalieri d’Oro, L.; Rognoni, M.; Fusco, M.; Vitale, M.F.; Usala, M.; Cusimano, R.; Mazzucco, W.; Michiara, M.; Sgargi, P.; Boschetti, L.; Borciani, E.; Seghini, P.; Maule, M.M.; Merletti, F.; Tumino, R.; Mancuso, P.; Vicentini, M.; Cassetti, T.; Sassatelli, R.; Falcini, F.; Giorgetti, S.; Caiazzo, A.L.; Cavallo, R.; Cesaraccio, R.; Pirino, D.R.; Contrino, M.L.; Tisano, F.; Fanetti, A.C.; Maspero, S.; Carone, S.; Mincuzzi, A.; Candela, G.; Scuderi, T.; Gentilini, M.A.; Piffer, S.; Rosso, S.; Barchielli, A.; Caldarella, A.; Bianconi, F.; Stracci, F.; Contiero, P.; Tagliabue, G.; Rugge, M.; Zorzi, M.; Beggiato, S.; Brustolin, A.; Berrino, F.; Gatta, G.; Sant, M.; Buzzoni, C.; Mangone, L.; Capocaccia, R.; De Angelis, R.; Zanetti, R.; Maurina, A.; Pildava, S.; Lipunova, N.; Vincerževskiené, I.; Agius, D.; Calleja, N.; Siesling, S.; Larønningen, S.; Møller, B.; Dyzmann-Sroka, A.; Trojanowski, M.; Góźdź, S.; Mężyk, R.; Mierzwa, T.; Molong, L.; Rachtan, J.; Szewczyk, S.; Błaszczyk, J.; Kępska, K.; Kościańska, B.; Tarocińska, K.; Zwierko, M.; Drosik, K.; Maksimowicz, K.M.; Purwin-Porowska, E.; Reca, E.; Wójcik-Tomaszewska, J.; Tukiendorf, A.; Grądalska-Lampart, M.; Radziszewska, A.U.; Gos, A.; Talerczyk, M.; Wyborska, M.; Didkowska, J.A.; Wojciechowska, U.; Bielska-Lasota, M.; Forjaz de Lacerda, G.; Rego, R.A.; Bastos, J.; Silva, M.A.; Antunes, L.; Laranja Pontes, J.; Mayer-da-Silva, A.; Miranda, A.; Blaga, L.M.; Coza, D.; Gusenkova, L.; Lazarevich, O.; Prudnikova, O.; Vjushkov, D.M.; Egorova, A.G.; Orlov, A.E.; Kudyakov, L.A.; Pikalova, L.V.; Adamcik, J.; Safaei Diba, C.; Primic-Žakelj, M.; Zadnik, V.; Larrañaga, N.; Lopez de Munain, A.; Herrera, A.A.; Redondas, R.; Marcos-Gragera, R.; Vilardell Gil, M.L.; Molina, E.; Sánchez Perez, M.J.; Franch Sureda, P.; Ramos Montserrat, M.; Chirlaque, M.D.; Navarro, C.; Ardanaz, E.E.; Guevara, M.M.; Fernández-Delgado, R.; Peris-Bonet, R.; Carulla, M.; Galceran, J.; Alberich, C.; Vicente-Raneda, M.; Khan, S.; Pettersson, D.; Dickman, P.; Avelina, I.; Staehelin, K.; Camey, B.; Bouchardy, C.; Schaffar, R.; Frick, H.; Herrmann, C.; Bulliard, J.L.; Maspoli-Conconi, M.; Kuehni, C.E.; Redmond, S.M.; Bordoni, A.; Ortelli, L.; Chiolero, A.; Konzelmann, I.; Matthes, K.L.; Rohrmann, S.; Broggio, J.; Rashbass, J.; Fitzpatrick, D.; Gavin, A.; Clark, D.I.; Deas, A.J.; Huws, D.W.; White, C.; Montel, L.; Rachet, B.; Turculet, A.D.; Stephens, R.; Chalker, E.; Phung, H.; Walton, R.; You, H.; Guthridge, S.; Johnson, F.; Gordon, P.; D’Onise, K.; Priest, K.; Stokes, B.C.; Venn, A.; Farrugia, H.; Thursfield, V.; Dowling, J.; Currow, D.; Hendrix, J.; Lewis, C. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125), 1023-1075.
[http://dx.doi.org/10.1016/S0140-6736(17)33326-3] [PMID: 29395269]
[5]
Kazi, D.S.; Penko, J.M.; Bibbins-Domingo, K. Statins for primary prevention of cardiovascular disease. Med. Clin. North Am., 2017, 101(4), 689-699.
[http://dx.doi.org/10.1016/j.mcna.2017.03.001] [PMID: 28577620]
[6]
Jiang, W.; Hu, J.W.; He, X.R.; Jin, W.L.; He, X.Y. Statins: A repurposed drug to fight cancer. J. Exp. Clin. Cancer Res., 2021, 40(1), 241.
[http://dx.doi.org/10.1186/s13046-021-02041-2] [PMID: 34303383]
[7]
Lou, D.; Fu, R.; Gu, L.; Su, H.; Guan Association between statins’ exposure with incidence and prognosis of gastric cancer: an updated meta-analysis. Expert Rev. Clin. Pharmacol., 2022, 15(9), 1127-1138.
[http://dx.doi.org/10.1080/17512433.2022.2112178] [PMID: 35947078]
[8]
Rodríguez-Miguel, A.; Fernández-Antón, E.; Barreira-Hernández, D.; García-Rodríguez, L.A.; Gil, M.; García-Lledó, A.; De Abajo, F.J. Statins and colorectal cancer risk: A population-based case-control study and synthesis of the epidemiological evidence. J. Clin. Med., 2022, 11(6), 1528.
[http://dx.doi.org/10.3390/jcm11061528] [PMID: 35329853]
[9]
Islam, M.M.; Yang, H.C.; Nguyen, P.A.; Poly, T.N.; Huang, C.W.; Kekade, S.; Khalfan, A.M.; Debnath, T.; Li, Y.C.J.; Abdul, S.S. Exploring association between statin use and breast cancer risk: An updated meta-analysis. Arch. Gynecol. Obstet., 2017, 296(6), 1043-1053.
[http://dx.doi.org/10.1007/s00404-017-4533-3] [PMID: 28940025]
[10]
Yang, L.; Wei, Q.; Tan, P.; Zhang, C.; Wei, S-Y.; Tang, Z.; Gao, L. Effect of statins type on incident prostate cancer risk: A meta-analysis and systematic review. Asian J. Androl., 2017, 19(6), 666-671.
[http://dx.doi.org/10.4103/1008-682X.190327] [PMID: 27924788]
[11]
Wang, Y.; Wang, W.; Wang, M.; Shi, J.; Jia, X.; Dang, S. A meta-analysis of statin use and risk of hepatocellular carcinoma. Can. J. Gastroenterol. Hepatol., 2022, 2022, 1-15.
[http://dx.doi.org/10.1155/2022/5389044] [PMID: 35356132]
[12]
Facciorusso, A.; Abd El Aziz, M.A.; Singh, S.; Pusceddu, S.; Milione, M.; Giacomelli, L.; Sacco, R. Statin use decreases the incidence of hepatocellular carcinoma: An updated meta-analysis. Cancers, 2020, 12(4), 874.
[http://dx.doi.org/10.3390/cancers12040874] [PMID: 32260179]
[13]
Climent, E.; Benaiges, D.; Pedro-Botet, J. Hydrophilic or lipophilic statins? Front. Cardiovasc. Med., 2021, 8, 687585.
[http://dx.doi.org/10.3389/fcvm.2021.687585] [PMID: 34095267]
[14]
Murphy, C.; Deplazes, E.; Cranfield, C.G.; Garcia, A. The role of structure and biophysical properties in the pleiotropic effects of statins. Int. J. Mol. Sci., 2020, 21(22), 8745.
[http://dx.doi.org/10.3390/ijms21228745] [PMID: 33228116]
[15]
Liu, Y.; Tang, W.; Wang, J.; Xie, L.; Li, T.; He, Y.; Deng, Y.; Peng, Q.; Li, S.; Qin, X. Association between statin use and colorectal cancer risk: A meta-analysis of 42 studies. Cancer Causes Control, 2014, 25(2), 237-249.
[http://dx.doi.org/10.1007/s10552-013-0326-6] [PMID: 24265089]
[16]
Babcook, M.A.; Joshi, A.; Montellano, J.A.; Shankar, E.; Gupta, S. Statin use in prostate cancer: An update. Nutr. Metab. Insights, 2016, 9, NMI.S38362.
[http://dx.doi.org/10.4137/NMI.S38362] [PMID: 27441003]
[17]
Shi, M.; Zheng, H.; Nie, B.; Gong, W.; Cui, X. Statin use and risk of liver cancer: An update meta-analysis. BMJ Open, 2014, 4(9), e005399.
[http://dx.doi.org/10.1136/bmjopen-2014-005399] [PMID: 25227628]
[18]
Chang, Y.; Liu, Q.; Zhou, Z.; Ding, Y.; Yang, M.; Xu, W.; Chen, K.; Zhang, Q.; Wang, Z.; Li, H. Can statin treatment reduce the risk of hepatocellular carcinoma? a systematic review and meta-analysis. Technol. Cancer Res. Treat., 2020, 19
[http://dx.doi.org/10.1177/1533033820934881] [PMID: 32552476]
[19]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021, 372(71), n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[20]
El-Serag, H.B.; Johnson, M.L.; Hachem, C.; Morgana, R.O. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology, 2009, 136(5), 1601-1608.
[http://dx.doi.org/10.1053/j.gastro.2009.01.053] [PMID: 19208359]
[21]
Kim, G.; Jang, S.Y.; Han, E.; Lee, Y.; Park, S.; Nam, C.M.; Kang, E.S. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. Int. J. Cancer, 2017, 140(4), 798-806.
[http://dx.doi.org/10.1002/ijc.30506] [PMID: 27861855]
[22]
Kim, G.; Jang, S.Y.; Nam, C.M.; Kang, E.S. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. J. Hepatol., 2018, 68(3), 476-484.
[http://dx.doi.org/10.1016/j.jhep.2017.10.018] [PMID: 29107150]
[23]
Kim, H.W.; Joo, Y.S.; Kang, S.C.; Koh, H.B.; Han, S.H.; Yoo, T.H.; Kang, S.W.; Park, J.T. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci. Rep., 2022, 12(1), 10807.
[http://dx.doi.org/10.1038/s41598-022-14713-w] [PMID: 35752695]
[24]
Lai, S.W.; Liao, K.F.; Lai, H.C.; Muo, C.H.; Sung, F.C.; Chen, P.C. Statin use and risk of hepatocellular carcinoma. Eur. J. Epidemiol., 2013, 28(6), 485-492.
[http://dx.doi.org/10.1007/s10654-013-9806-y] [PMID: 23681775]
[25]
McGlynn, K.A.; Hagberg, K.; Chen, J.; Graubard, B.I.; London, W.T.; Jick, S.; Sahasrabuddhe, V.V. Statin use and risk of primary liver cancer in the clinical practice research datalink. J. Natl. Cancer Inst., 2015, 107(4), djv009.
[http://dx.doi.org/10.1093/jnci/djv009] [PMID: 25722350]
[26]
Pinyopornpanish, K.; Al-Yaman, W.; Butler, R.S.; Carey, W.; McCullough, A.; Romero-Marrero, C. Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis. Am. J. Gastroenterol., 2021, 116(11), 2258-2269.
[http://dx.doi.org/10.14309/ajg.0000000000001347] [PMID: 34212895]
[27]
Sung, F.C.; Yeh, Y.T.; Muo, C.H.; Hsu, C.C.; Tsai, W.C.; Hsu, Y.H. Statins reduce hepatocellular carcinoma risk in patients with chronic kidney disease and end-stage renal disease: A 17-year longitudinal study. Cancers, 2022, 14(3), 825.
[http://dx.doi.org/10.3390/cancers14030825] [PMID: 35159093]
[28]
Tran, K.T.; McMenamin, Ú.C.; Coleman, H.G.; Cardwell, C.R.; Murchie, P.; Iversen, L.; Lee, A.J.; Thrift, A.P. Statin use and risk of liver cancer: Evidence from two population-based studies. Int. J. Cancer, 2020, 146(5), 1250-1260.
[http://dx.doi.org/10.1002/ijc.32426] [PMID: 31112291]
[29]
Tsan, Y.T.; Lee, C.H.; Wang, J.D.; Chen, P.C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J. Clin. Oncol., 2012, 30(6), 623-630.
[http://dx.doi.org/10.1200/JCO.2011.36.0917] [PMID: 22271485]
[30]
Zou, B.; Odden, M.C.; Nguyen, M.H. Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol., 2022.
[PMID: 35158055]
[31]
Sutter, A.P.; Maaser, K.; Höpfner, M.; Huether, A.; Schuppan, D.; Scherübl, H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J. Hepatol., 2005, 43(5), 808-816.
[http://dx.doi.org/10.1016/j.jhep.2005.04.010] [PMID: 16083991]
[32]
Relja, B.; Meder, F.; Wilhelm, K.; Henrich, D.; Marzi, I.; Lehnert, M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int. J. Mol. Med., 2010, 26(5), 735-741.
[http://dx.doi.org/10.3892/ijmm_00000520] [PMID: 20878096]
[33]
Cao, Z.; Fan-Minogue, H.; Bellovin, D.I.; Yevtodiyenko, A.; Arzeno, J.; Yang, Q.; Gambhir, S.S.; Felsher, D.W. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res., 2011, 71(6), 2286-2297.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-3367] [PMID: 21262914]
[34]
Shachaf, C.M.; Kopelman, A.M.; Arvanitis, C.; Karlsson, Å.; Beer, S.; Mandl, S.; Bachmann, M.H.; Borowsky, A.D.; Ruebner, B.; Cardiff, R.D.; Yang, Q.; Bishop, J.M.; Contag, C.H.; Felsher, D.W. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature, 2004, 431(7012), 1112-1117.
[http://dx.doi.org/10.1038/nature03043] [PMID: 15475948]
[35]
Kopecka, J.; Trouillas, P.; Gašparović, A.Č.; Gazzano, E.; Assaraf, Y.G.; Riganti, C. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. Drug Resist. Updat., 2020, 49, 100670.
[http://dx.doi.org/10.1016/j.drup.2019.100670] [PMID: 31846838]
[36]
Jiang, P.; Mukthavaram, R.; Chao, Y.; Nomura, N.; Bharati, I. S.; Fogal, V.; Pastorino, S.; Teng, D.; Cong, X.; Pingle, S. C.; Kapoor, S.; Shetty, K.; Aggrawal, A.; Vali, S.; Abbasi, T.; Chien, S.; Kesari, S. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer, 2014, 111(8), 1562-1571.
[http://dx.doi.org/10.1038/bjc.2014.431]
[37]
Jang, H.J.; Hong, E.M.; Kim, M.; Kim, J.H.; Jang, J.; Park, S.W.; Byun, H.W.; Koh, D.H.; Choi, M.H.; Kae, S.H.; Lee, J. Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer. Oncotarget, 2016, 7(29), 46219-46229.
[38]
Wei, T.T.; Lin, Y.T.; Chen, W.S.; Luo, P.; Lin, Y.C.; Shun, C.T.; Lin, Y.H.; Chen, J.B.; Chen, N.W.; Fang, J.M.; Wu, M.S.; Yang, K.C.; Chang, L.C.; Tai, K.Y.; Liang, J.T.; Chen, C.C. Dual targeting of 3-hydroxy-3-methylglutaryl coenzyme a reductase and histone deacetylase as a therapy for colorectal cancer. EBioMedicine, 2016, 10, 124-136.
[http://dx.doi.org/10.1016/j.ebiom.2016.07.019] [PMID: 27448759]
[39]
Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam. Clin. Pharmacol., 2005, 19(1), 117-125.
[http://dx.doi.org/10.1111/j.1472-8206.2004.00299.x] [PMID: 15660968]
[40]
Egom, E.E.A.; Hafeez, H. Biochemistry of statins. Adv. Clin. Chem., 2016, 73, 127-168.
[http://dx.doi.org/10.1016/bs.acc.2015.10.005] [PMID: 26975972]
[41]
Ye, J.; Wang, C.; Sumpter, R., Jr; Brown, M.S.; Goldstein, J.L.; Gale, M., Jr Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc. Natl. Acad. Sci., 2003, 100(26), 15865-15870.
[http://dx.doi.org/10.1073/pnas.2237238100] [PMID: 14668447]
[42]
Zhao, T.T.; Le Francois, B.G.; Goss, G.; Ding, K.; Bradbury, P.A.; Dimitroulakos, J. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: Potential regulation by targeting rho proteins. Oncogene, 2010, 29(33), 4682-4692.
[http://dx.doi.org/10.1038/onc.2010.219] [PMID: 20562912]
[43]
Lupberger, J.; Zeisel, M.B.; Xiao, F.; Thumann, C.; Fofana, I.; Zona, L.; Davis, C.; Mee, C.J.; Turek, M.; Gorke, S.; Royer, C.; Fischer, B.; Zahid, M.N.; Lavillette, D.; Fresquet, J.; Cosset, F.L.; Rothenberg, S.M.; Pietschmann, T.; Patel, A.H.; Pessaux, P.; Doffoël, M.; Raffelsberger, W.; Poch, O.; McKeating, J.A.; Brino, L.; Baumert, T.F. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med., 2011, 17(5), 589-595.
[http://dx.doi.org/10.1038/nm.2341] [PMID: 21516087]
[44]
Li, X.; Sheng, L.; Liu, L.; Hu, Y.; Chen, Y.; Lou, L. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: A meta-analysis. BMC Gastroenterol., 2020, 20(1), 98.
[http://dx.doi.org/10.1186/s12876-020-01222-1] [PMID: 32272891]
[45]
Goh, M.J.; Sinn, D.H.; Kim, S.; Woo, S.Y.; Cho, H.; Kang, W.; Gwak, G.Y.; Paik, Y.H.; Choi, M.S.; Lee, J.H.; Koh, K.C.; Paik, S.W. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology, 2020, 71(6), 2023-2032.
[http://dx.doi.org/10.1002/hep.30973] [PMID: 31556128]
[46]
Fang, C.; Pan, J.; Qu, N.; Lei, Y.; Han, J.; Zhang, J.; Han, D. The AMPK pathway in fatty liver disease. Front. Physiol., 2022, 13, 970292.
[http://dx.doi.org/10.3389/fphys.2022.970292] [PMID: 36203933]
[47]
Fatima, K.; Moeed, A.; Waqar, E.; Atif, A.R.; Kamran, A.; Rizvi, H.; Suri, N.F.; Haider, H.; Shuja, S.H.; Khalid, M.; Minhas, A.M.K. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis. Clin. Res. Hepatol. Gastroenterol., 2022, 46(4), 101816.
[http://dx.doi.org/10.1016/j.clinre.2021.101816] [PMID: 34607067]
[48]
Boutari, C.; Pappas, P.D.; Anastasilakis, D.; Mantzoros, C.S. Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin. Nutr., 2022, 41(10), 2195-2206.
[http://dx.doi.org/10.1016/j.clnu.2022.08.001] [PMID: 36081293]
[49]
Lee, S.H.; Choi, N.Y.; Yu, H.J.; Park, J.; Choi, H.; Lee, K.Y.; Huh, Y.M.; Lee, Y.J.; Koh, S.H. Atorvastatin protects NSC-34 motor neurons against oxidative stress by activating PI3K, ERK and free radical scavenging. Mol. Neurobiol., 2016, 53(1), 695-705.
[http://dx.doi.org/10.1007/s12035-014-9030-0] [PMID: 25577170]
[50]
Trebicka, J.; Hennenberg, M.; Odenthal, M.; Shir, K.; Klein, S.; Granzow, M.; Vogt, A.; Dienes, H.P.; Lammert, F.; Reichen, J.; Heller, J.; Sauerbruch, T. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J. Hepatol., 2010, 53(4), 702-712.
[http://dx.doi.org/10.1016/j.jhep.2010.04.025] [PMID: 20633948]
[51]
Kim, M.H.; Kim, M.Y.; Salloum, S.; Qian, T.; Wong, L.P.; Xu, M.; Lee, Y.; Shroff, S.G.; Sadreyev, R.I.; Corey, K.E.; Baumert, T.F.; Hoshida, Y.; Chung, R.T. Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. Hepatol. Commun., 2022, 6(9), 2581-2593.
[http://dx.doi.org/10.1002/hep4.1991] [PMID: 35712812]
[52]
Yu, Z.; Guo, J.; Liu, Y.; Wang, M.; Liu, Z.; Gao, Y.; Huang, L. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. J. Nanobiotechnology, 2022, 20(1), 9.
[http://dx.doi.org/10.1186/s12951-021-01205-8] [PMID: 34983554]
[53]
Liu, S.; Uppal, H.; Demaria, M.; Desprez, P. Y.; Campisi, J.; Kapahi, P. Simvastatin suppresses breast cancer cell proliferation induced by senescent cells. Sci Rep, 2015, 5, 17895.
[http://dx.doi.org/10.1038/srep17895]
[54]
Xie, L.; Zhu, G.; Shang, J.; Chen, X.; Zhang, C.; Ji, X.; Zhang, Q.; Wei, Y. An overview on the biological activity and anti-cancer mechanism of lovastatin. Cell. Signal., 2021, 87, 110122.
[http://dx.doi.org/10.1016/j.cellsig.2021.110122] [PMID: 34438015]
[55]
Deezagi, A.; Safari, N. Rosuvastatin inhibit spheroid formation and epithelial–mesenchymal transition (EMT) in prostate cancer PC-3 cell line. Mol. Biol. Rep., 2020, 47(11), 8727-8737.
[http://dx.doi.org/10.1007/s11033-020-05918-1] [PMID: 33085048]
[56]
Jiao, Z.; Cai, H.; Long, Y.; Sirka, O.K.; Padmanaban, V.; Ewald, A.J.; Devreotes, P.N. Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects. Proc. Natl. Acad. Sci., 2020, 117(8), 4158-4168.
[http://dx.doi.org/10.1073/pnas.1917938117] [PMID: 32051246]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy